English  |  正體中文  |  简体中文  |  Post-Print筆數 : 27 |  Items with full text/Total items : 113648/144635 (79%)
Visitors : 51593922      Online Users : 907
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: https://nccur.lib.nccu.edu.tw/handle/140.119/22337


    Title: Utilization of hepatoprotectants within the National Health Insurance in Taiwan
    Authors: Chen,Tzeng-Ji;周麗芳;Hwang,Shinn-Jang
    Keywords: drug utilization;liver diseases;national health programs;pharmacoepidemiology;protective agents
    Date: 2003-07
    Issue Date: 2009-01-06 15:25:15 (UTC+8)
    Abstract: Background: Although the hepatoprotectants of Western medicine have centuries of history, their utilization patterns have been seldom documented. Because the National Health Insurance program in Taiwan reimburses hepatoprotectant use, we could estimate the age- and sex-specific prevalence and utilization patterns of hepatoprotectants in Western medicine within the health insurance system in Taiwan. Methods: We analyzed the outpatient prescription data of 50 000 randomly sampled insured patients in 2000. Only patients using drugs indicated for liver diseases and diagnostic codes related to liver diseases on the same visit were considered to be receiving hepatoprotectants. Drugs involved in Chinese medicine were not included. Results: Among the valid cohort of 46 614 people, 783 (1.7%) were identified as patients with liver disease and receiving hepatoprotectants. Highest prevalence of hepatoprotectant use was 4.9% in the 60–69 years age group. Silymarin, multivitamins, methionine, ursodeoxycholic acid, and liver hydrolysate accounted for 88.8% of the 3215 prescribed items of hepatoprotectants. Patients receiving hepatoprotectants had, on average, visited the clinics more frequently than those not using hepatoprotectants (30 vs 14 times in a year, P < 0.001), and used more insurance benefits (US$1352 vs US$456, P < 0.001). Conclusions: The frequency of use of major hepatoprotectants in Taiwan corresponded to the current modalities of treatment under discussion worldwide. © 2003 Blackwell Publishing Asia Pty Ltd.
    Relation: Journal of Gastroenterology and Hepatology, 18(7), 868-872
    Data Type: article
    DOI 連結: http://dx.doi.org/10.1046/j.1440-1746.2003.03078.x
    DOI: 10.1046/j.1440-1746.2003.03078.x
    Appears in Collections:[財政學系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    j.1440-1746.pdf68KbAdobe PDF21231View/Open


    All items in 政大典藏 are protected by copyright, with all rights reserved.


    社群 sharing

    著作權政策宣告 Copyright Announcement
    1.本網站之數位內容為國立政治大學所收錄之機構典藏，無償提供學術研究與公眾教育等公益性使用，惟仍請適度，合理使用本網站之內容，以尊重著作權人之權益。商業上之利用，則請先取得著作權人之授權。
    The digital content of this website is part of National Chengchi University Institutional Repository. It provides free access to academic research and public education for non-commercial use. Please utilize it in a proper and reasonable manner and respect the rights of copyright owners. For commercial use, please obtain authorization from the copyright owner in advance.

    2.本網站之製作，已盡力防止侵害著作權人之權益，如仍發現本網站之數位內容有侵害著作權人權益情事者，請權利人通知本網站維護人員(nccur@nccu.edu.tw)，維護人員將立即採取移除該數位著作等補救措施。
    NCCU Institutional Repository is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff(nccur@nccu.edu.tw). We will remove the work from the repository and investigate your claim.
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback